Article
Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.
The Lancet. Oncology - 1 Dec 2014
Franz David Neal, Belousova Elena, Sparagana Steven, Bebin E Martina, Frost Michael, Kuperman Rachel, Witt Olaf, Kohrman Michael H, Flamini J Robert, Wu Joyce Y, Curatolo Paolo, de Vries Petrus J, Berkowitz Noah, Anak Oezlem, Niolat Julie, Jozwiak Sergiusz
Abstract excerpt
BACKGROUND: In the EXIST-1 trial, initiated on Aug 10, 2009, more than 35% of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex had at least 50% reduction in SEGA volume after 9·6 months of treatment with everolimus. In this Article, we report interim data (up to Jan 11, 2013) to support longer-term tolerability and efficacy of everolimus from the continuing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.